Neuropathic cancer pain: prevalence, pathophysiology, and management
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is reported to be as high as 40%. The etiologies of NCP include direct nerve invasion or nerve compression by the cancer, neural toxicity, chemotherapy, and radiotherapy. NCP is subdivided into plexopathy, radiculopathy, and peripheral neuropathies, among several other categories. The clinical characteristics of NCP differ from those of nociceptive pain in terms of both the hypersensitivity symptoms (burning, tingling, and an electrical sensation) and the hyposensitivity symptoms (numbness and muscle weakness). Recovery requires several months to years, even after recovery from injury. Management is complex; NCP does not usually respond to opioids, although treatments may feature both opioids and adjuvant drugs including antidepressants, anticonvulsants, and anti-arrhythmic agents, all of which improve the quality-of-life. This review addresses the pathophysiology, clinical characteristics and management of NCP, and factors rendering pain control difficult.
Abstract
Neuropathic cancer pain (NCP) is caused by nerve damage attributable to the cancer per se, and/or treatments including chemotherapy, radiotherapy, and surgery; the prevalence is reported to be as high as 40%. The etiologies of NCP include direct nerve invasion or nerve compression by the cancer, neural toxicity, chemotherapy, and radiotherapy. NCP is subdivided into plexopathy, radiculopathy, and peripheral neuropathies, among several other categories. The clinical characteristics of NCP differ from those of nociceptive pain in terms of both the hypersensitivity symptoms (burning, tingling, and an electrical sensation) and the hyposensitivity symptoms (numbness and muscle weakness). Recovery requires several months to years, even after recovery from injury. Management is complex; NCP does not usually respond to opioids, although treatments may feature both opioids and adjuvant drugs including antidepressants, anticonvulsants, and anti-arrhythmic agents, all of which improve the quality-of-life. This review addresses the pathophysiology, clinical characteristics and management of NCP, and factors rendering pain control difficult.
참고문헌 (51)
- van den Beuken-van Everdingen MH, "Prevalence of pain in patients with cancer: a systematic review of the past 40 years", Ann Oncol, 18, pp.1437~1449 (2007)
- Oldenmenger WH, "A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal", Eur J Cancer, 45, pp.1370~1380 (2009)
- Bennett MI, "Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review", Pain, 153, pp.359~365 (2012)
- Nicholson B., "Differential diagnosis: nociceptive and neuropathic pain", Am J Manag Care, 12(9 Suppl), pp.S256~S262 (2006)
- Lema MJ, "Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain", Oncologist, 15(Suppl 2), pp.3~8 (2010)
- Treede RD, "Neuropathic pain: redefinition and a grading system for clinical and research purposes", Neurology, 70, pp.1630~1635 (2008)
- Oosterling A, "Neuropathic pain components in patients with cancer: prevalence, treatment, and interference with daily activities", Pain Pract, 16, pp.413~421 (2016)
- Oh SY, "Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients", Support Care Cancer, 25, pp.3759~3767 (2017)
- Rayment C, "Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study", Palliat Med, 27, pp.714~721 (2013)
- Garzon-Rodriguez C, "Cancer-related neuropathic pain in out-patient oncology clinics: a European survey", BMC Palliat Care, 12, pp.41~ (2013)
- Boland EG, "Classification of neuropathic pain in cancer patients", Curr Opin Support Palliat Care, 9, pp.112~115 (2015)
- Fallon MT, "Neuropathic pain in cancer", Br J Anaesth, 111, pp.105~111 (2013)
- Urch CE, "Neuropathic pain in cancer", Eur J Cancer, 44, pp.1091~1096 (2008)
- Vecht CJ, "Nociceptive nerve pain and neuropathic pain", Pain, 39, pp.243~246 (1989)
- Seretny M, "Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis", Pain, 155, pp.2461~2470 (2014)
- Sisignano M, "Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain", Nat Rev Neurol, 10, pp.694~707 (2014)
- Park SB, "Chemotherapy-induced peripheral neurotoxicity: a critical analysis", CA Cancer J Clin, 63, pp.419~437 (2013)
- Fernandes R, "Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy: a systematic review", Support Care Cancer, 24, pp.1583~1594 (2016)
- Loprinzi CL, "Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1", J Clin Oncol, 29, pp.1472~1478 (2011)
- Reeves BN, "Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy:North Central Cancer Treatment Group trial N08C1", Cancer, 118, pp.5171~5178 (2012)
- Griffith KA, "Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer", J Pain Symptom Manage, 54, pp.701~706 (2017)
- Pachman DR, "Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III Trial N08CB (Alliance)", J Clin Oncol, 33, pp.3416~3422 (2015)
- Ventzel L, "Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel", Pain, 157, pp.560~568 (2016)
- Loprinzi CL, "The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism", Cancer J, 13, pp.399~403 (2007)
- Grisold W, "Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention", Neuro Oncol, 14(Suppl 4), pp.iv45~iv54 (2012)
- Rivera E, "Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer", Cancer Chemother Pharmacol, 75, pp.659~670 (2015)
- Finnerup NB, "Neuropathic pain: an updated grading system for research and clinical practice", Pain, 157, pp.1599~1606 (2016)
- Bennett M., "The LANSS Pain Scale: the leeds assessment of neuropathic symptoms and signs", Pain, 92, pp.147~157 (2001)
- 박철희, "Cross-cultural Adaptation and Linguistic Validation of the Korean Version of the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale", Journal of Korean Medical Science, 30(9), pp.1334~1339 (2015), 대한의학회
- Bouhassira D, "Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)", Pain, 114, pp.29~36 (2005)
- 김호중, "Validation of the Korean Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain in Patients with Lumbar or Lumbar-Radicular Pain", Yonsei Medical Journal, 57(2), pp.449~454 (2016), 연세대학교의과대학[DOI]
- Abdallah FW, "Comparing the DN4 tool with the IASP grading system for chronic neuropathic pain screening after breast tumor resection with and without paravertebral blocks: a prospective 6-month validation study", Pain, 156, pp.740~749 (2015)
- Freynhagen R, "PainDETECT:a new screening questionnaire to identify neuropathic components in patients with back pain", Curr Med Res Opin, 22, pp.1911~1920 (2006)
- Cruccu G, "EFNS guidelines on neuropathic pain assessment: revised 2009", Eur J Neurol, 17, pp.1010~1018 (2009)
- Rog DJ, "Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis", Clin J Pain, 23, pp.473~481 (2007)
- Bouhassira D, "Development and validation of the neuropathic pain symptom inventory", Pain, 108, pp.248~257 (2004)
- Valeriani M, "Clinical usefulness of laser evoked potentials", Neurophysiol Clin, 42, pp.345~353 (2012)
- Backonja MM, "Value of quantitative sensory testing in neurological and pain disorders:NeuPSIG consensus", Pain, 154, pp.1807~1819 (2013)
- Terkelsen AJ, "The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes", Lancet Neurol, 16, pp.934~944 (2017)
- Chan AC, "Small fiber neuropathy: getting bigger!", Muscle Nerve, 53, pp.671~682 (2016)
- Hershman DL, "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 32, pp.1941~1967 (2014)
- Freynhagen R, "Diagnosis and management of neuropathic pain", BMJ, 339, pp.b3002~ (2009)
- Moore RA, "Amitriptyline for neuropathic pain in adults", Cochrane Database Syst Rev, (7), pp.CD008242~ (2015)
- Smith EM, "Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:a randomized clinical trial", JAMA, 309, pp.1359~1367 (2013)
- Henry NL, "Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202", J Clin Oncol, 36, pp.326~332 (2018)
- Durand JP, "Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial", Ann Oncol, 23, pp.200~205 (2012)
- Mishra S, "A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study", Am J Hosp Palliat Care, 29, pp.177~182 (2012)
- de Andrade DC, "Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial", Oncologist, 22 (2017)
- Finnerup NB, "Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis", Lancet Neurol, 14, pp.162~173 (2015)
- Knezevic NN, "Management of chronic neuropathic pain with single and compounded topical analgesics", Pain Manag, 7, pp.537~558 (2017)